DTC
VRNA

Deep Track Capital’s Verona Pharma VRNA Stock Holding History

Deep Track Capital’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-850,000
Closed -$39.5M – 79
2024
Q4 		$39.5M Sell
850,000
-2,330,025
-73% -$87.5M 1.47% 22
2024
Q3 		$91.5M Sell
3,180,025
-819,975
-20% -$20.2M 2.9% 12
2024
Q2 		$57.8M Buy
4,000,000
+812,585
+25% +$11.9M 1.73% 22
2024
Q1 		$51.3M Hold
3,187,415
– – 1.47% 27
2023
Q4 		$63.4M Hold
3,187,415
– – 2.12% 17
2023
Q3 		$52M Hold
3,187,415
– – 2.01% 18
2023
Q2 		$67.4M Hold
3,187,415
– – 3.12% 14
2023
Q1 		$64M Hold
3,187,415
– – 2.63% 13
2022
Q4 		$83.3M Buy
3,187,415
+358,321
+13% +$4.77M 3.5% 8
2022
Q3 		$28.9M Buy
+2,829,094
New +$23.8M 1.32% 28

Other funds holding VRNA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deep Track Capital's VRNA Position: Q1 2025 in Review

Deep Track Capital sold out of Verona Pharma (VRNA) in Q1 2025, closing a stake of 850,000 shares — an estimated $39.5M sold.

Deep Track Capital first reported a position in VRNA in Q3 2022 and held it in 10 quarters. The position peaked at $91.5M in Q3 2024. 258 funds tracked by Wall St. Rank hold VRNA as of Q1 2025.

  • Deep Track Capital reported no remaining Verona Pharma position as of Q1 2025 after selling out during the quarter.
  • Deep Track Capital sold 850,000 Verona Pharma shares in Q1 2025, an estimated $39.5M.
  • Deep Track Capital first reported a position in Verona Pharma in Q3 2022 and held it in 10 quarters.
  • Deep Track Capital's Verona Pharma position peaked at $91.5M in Q3 2024.
  • 258 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2025.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.